India May Scrap 60 percent Shelf Life Rule for Imported Drugs

The Imported Drug Shelf Life Rule could soon see a major change in India.

The Central government has proposed scrapping the existing 60 percent  residual shelf life requirement for imported medicines and replacing it with a simpler 12-month rule.

The proposed Imported Drug Shelf Life Rule aims to reduce medicine wastage, make imports easier, and improve the availability of drugs in the country.

The move is expected to benefit pharmaceutical companies while ensuring that medicines entering India continue to meet quality and safety standards.

What Is Changing in the Imported Drug Shelf Life Rule?

At present, imported medicines must have more than 60 percent  of their total shelf life remaining when they arrive in India. This rule applies regardless of whether the medicine has a shelf life of two years, five years, or longer.

The Health Ministry has now proposed amending Rule 31 of the Drugs Rules, 1945. If approved, imported medicines will only need to have at least 12 months of residual shelf life at the time of import.

For example, a medicine with a total shelf life of five years currently needs more than three years of shelf life remaining before it can be imported. Under the proposed rule, the same medicine can be imported even if it has only 12 months left before expiry.

The proposal is part of a draft notification issued by the ministry, and stakeholders have been invited to submit their comments before the rule is finalized.

Also Read: Scaling Perfusion Technology from Lab Success to Manufacturing Reality

Why the Government Wants to Change the Rule

The proposed change is aimed at reducing the unnecessary wastage of imported medicines while making the import process more practical.

Some of the key reasons behind the proposal include:

• Reducing wastage of imported medicines.
• Simplifying import regulations for pharmaceutical companies.
• Improving the availability of essential medicines in India.
• Making supply chains more efficient.
• Allowing better inventory management without compromising drug quality.

Officials believe the current percentage-based requirement can lead to unnecessary rejection of medicines that are still safe and effective for use.

What It Means for Pharma Companies and Patients

If the proposal is approved, pharmaceutical companies importing medicines into India could benefit from greater flexibility in managing their global supply chains. Medicines that previously failed to meet the 60 percent  shelf life requirement may become eligible for import as long as they have at least one year of remaining shelf life.

The government has made it clear that the proposed amendment does not reduce safety standards. Imported medicines will still need to comply with all applicable quality and regulatory requirements before they reach patients.

The draft amendment is currently open for public feedback. After reviewing suggestions from stakeholders, the government will decide whether to notify the revised Imported Drug Shelf Life Rule.

If implemented, the change could reduce medicine wastage, improve the availability of imported drugs, and make India's pharmaceutical import rules easier to follow while maintaining patient safety.